Exelixis, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael M. Morrissey
- Full Time Employees
- 1,077
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1851 Harbor Bay Parkway Alameda CA United States 94502
- IPO Date
- Apr 11, 2000
- CIK
- 0000939767
- Website
- exelixis.com
- Similar Companies
- Business
- Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX (cabozantinib) tablets for advanced renal cell carcinoma, hepatocellular carcinoma, and previously treated advanced neuroendocrine tumors; COMETRIQ (cabozantinib) capsules for metastatic medullary thyroid cancer; and COTELLIC (cobimetinib), partnered with Roche/Genentech for advanced melanoma. Exelixis advances a diversified pipeline of small-molecule therapeutics and biotherapeutics, including bispecific antibodies, antibody-drug conjugates, next-generation kinase inhibitors such as zanzalintinib in phase 3 trials for renal cell carcinoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck, and early-stage programs like XL309 targeting PARP inhibitors. Founded in 1994 and headquartered in Alameda, California, the company conducts global operations through strategic partnerships with Bristol Myers Squibb, Merck, Takeda Pharmaceutical, and others to expand development and commercialization reach. Recent developments include U.S. FDA approval of a new CABOMETYX indication for previously treated advanced neuroendocrine tumors; authorization of a $500 million stock repurchase program in February 2025 following completion of a prior $500 million program from August 2024, with over $1.2 billion returned to shareholders since March 2023; plans to initiate phase 3 trials for zanzalintinib in neuroendocrine tumors and two Merck-collaborated renal cell carcinoma studies in 2025; and ongoing enrollment in XL309 monotherapy and combination trials for PARP-refractory tumors.
Company News
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
What Exelixis (EXEL) Said on Its Q3 Earnings Call
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis Rises with Earnings on Tap
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Exelixis (NASDAQ:EXEL) Hits New 1-Year High – Here’s What Happened
Here's Why Exelixis (EXEL) is a Strong Value Stock
Exelixis Shares Rising on CABOMETYX Revenue
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?